Search results for " Squamous cell carcinoma"

showing 10 items of 118 documents

Metabolic Profile of Oral Squamous Carcinoma Cell Lines Relies on a Higher Demand of Lipid Metabolism in Metastatic Cells

2017

Tumor cells are subjected to a broad range of selective pressures. As a result of the imposed stress, subpopulations of surviving cells exhibit individual biochemical phenotypes that reflect metabolic reprograming. The present work aimed at investigating metabolic parameters of cells displaying increasing degrees of metastatic potential. The metabolites present in cell extracts fraction of tongue fibroblasts and of cell lines derived from human tongue squamous cell carcinoma lineages displaying increasing metastatic potential (SCC9 ZsG, LN1 and LN2) were analyzed by 1H NMR (nuclear magnetic resonance) spectroscopy. Living, intact cells were also examined by the non-invasive method of fluore…

0301 basic medicineCancer ResearchBioenergeticsOxidative phosphorylationlcsh:RC254-28203 medical and health sciences0302 clinical medicinemetastasismetabolic reprogrammingGlycolysisOriginal ResearchChemistryCatabolismLipid metabolismlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenscancer progressionmetabolomicsSquamous carcinomaCell biologyoral squamous cell carcinomanuclear magnetic resonance030104 developmental biologyOncologyCell culture030220 oncology & carcinogenesisNAD+ kinaseFrontiers in Oncology
researchProduct

Genome wide DNA methylation profiling identifies specific epigenetic features in high-risk cutaneous squamous cell carcinoma

2019

ABSTRACTCutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer. Although most cSCCs have good prognosis, a subgroup of high-risk cSCC has a higher frequency of recurrence and mortality. Therefore, the identification of molecular risk factors associated with this aggressive subtype is of major interest. In this work we carried out a global-scale approach to investigate the DNA-methylation profile in patients at different stages, from premalignant actinic keratosis to low-risk invasive and high-risk non-metastatic and metastatic cSCC. The results showed massive non-sequential changes in DNA-methylome and identified a minimal methylation signature that discriminates bet…

0301 basic medicineEpigenomicsMaleSkin NeoplasmsDiseaseBiochemistryActinic KeratosisGenomeEpigenesis Genetic0302 clinical medicineRisk FactorsMedicine and Health SciencesSkin TumorsAged 80 and overMultidisciplinaryDNA methylationQRSquamous Cell CarcinomasMethylationMiddle AgedPrognosisChromatinNucleic acidsGene Expression Regulation NeoplasticKeratosis ActinicOncology030220 oncology & carcinogenesisDNA methylationCarcinoma Squamous CellDisease ProgressionMedicineEpigeneticsFemaleDNA modificationChromatin modificationResearch ArticleChromosome biologyCell biologyCutaneous squamous cell carcinomaKeratosisScienceDermatologyBiologyCarcinomas03 medical and health sciencesDiagnostic MedicineCarcinomaGeneticsCancer Detection and DiagnosismedicineHumansEpigeneticsAgedNeoplasm StagingTreatment GuidelinesHealth Care PolicyBiology and life sciencesActinic keratosisCancers and NeoplasmsDNAmedicine.diseaseDNA FingerprintingDna methylation profilingHealth Care030104 developmental biologyCancer researchGene expressionNeoplasm Recurrence LocalSkin cancerGenome-Wide Association Study
researchProduct

Incidence trends of vulvar squamous cell carcinoma in Italy from 1990 to 2015

2020

The incidence of vulvar squamous cell carcinoma has increased for decades in most Western countries - a trend virtually restricted to women aged50 or 60 years. In southern Europe, conversely, the trends have been insufficiently studied. This article reports a study from Italy.Thirty-eight local cancer registries, currently covering 15,274,070 women, equivalent to 49.2% of the Italian national female population, participated. Invasive cancers registered between 1990 and 2015 with an International Classification of Diseases for Oncology, 3rd revision, topography code C51 and morphology codes compatible with vulvar squamous cell carcinoma (n = 6294) were eligible. Incidence trends were analyse…

0301 basic medicineHistoryVulvar Squamous Cell CarcinomaAge-period-cohort modelling; Incidence; Trend; Vulvar neoplasms; Carcinoma Squamous Cell; Female; History 20th Century; History 21st Century; Humans; Incidence; Italy; Middle Aged; Vulvar NeoplasmsSettore MED/42 - Igiene Generale E ApplicataHistory 21st CenturyNO03 medical and health sciences0302 clinical medicineAge-period-cohort modellingAge-period-cohort modelling; Incidence; Trend; Vulvar neoplasmsTrendHumansMedicineRisk factorVulvar neoplasmVulvar Neoplasmsbusiness.industryIncidenceIncidence (epidemiology)CarcinomaObstetrics and GynecologyHistory 20th CenturyMiddle Aged21st CenturyConfidence intervalCancer registry20th CenturyTrend analysis030104 developmental biologySquamous CellItalyOncology030220 oncology & carcinogenesisVulvar neoplasms incidence trend age-period-cohort modellingCarcinoma Squamous CellFemalebusinessDemographyCohort studyGynecologic Oncology
researchProduct

CD1A-positive cells and HSP60 (HSPD1) levels in keratoacanthoma and squamous cell carcinoma.

2015

CD1a is involved in presentation to the immune system of lipid antigen derived from tumor cells with subsequent T cell activation. Hsp60 is a molecular chaperone implicated in carcinogenesis by, for instance, modulating the immune reaction against the tumor. We have previously postulated a synergism between CD1a and Hsp60 as a key factor in the activation of an effective antitumor immune response in squamous epithelia. Keratoacantomas (KAs) are benign tumors that however can transform into squamous cell carcinomas (SCCs), but the reasons for this malignization are unknown. In a previous study, we found that CD1a-positive cells are significantly more numerous in KA than in SCC. In this study…

0301 basic medicineKeratoacanthomaCellmedicine.disease_causeBiochemistryAntigens CD10302 clinical medicineSquamous cell carcinomaAged 80 and overintegumentary systemPrognostic evaluationMiddle AgedHsp60ImmunohistochemistryKeratoacanthomamedicine.anatomical_structure030220 oncology & carcinogenesisCarcinoma Squamous CellImmunohistochemistryHSP60AdultT cellDifferential diagnosichemical and pharmacologic phenomenaCD1aBiologySettore MED/08 - Anatomia PatologicaDiagnosis DifferentialMitochondrial Proteins03 medical and health sciencesYoung AdultKeratoacantomaImmune systemmedicineBiomarkers TumorHumansAgedRetrospective StudiesOriginal PaperSettore BIO/16 - Anatomia UmanaCD1a; Differential diagnosis; Hsp60; Immunohistochemistry; Keratoacantoma; Prognostic evaluation; Squamous cell carcinoma; Treatment; Biochemistry; Cell BiologyfungiCell BiologyChaperonin 60medicine.diseaseTreatmentstomatognathic diseases030104 developmental biologyCancer researchDifferential diagnosisCarcinogenesisCell stresschaperones
researchProduct

Prognostic Nutritional Index as an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer.

2018

Background: Locally advanced head and neck squamous cell carcinoma (LAHNSCC) is a heterogeneous disease in which better predictive and prognostic factors are needed. Apart from TNM stage, both systemic inflammation and poor nutritional status have a negative impact on survival. Methods: We retrospectively analysed two independent cohorts of a total of 145 patients with LAHNSCC treated with induction chemotherapy followed by concurrent chemoradiotherapy at two different academic institutions. Full clinical data, including the Prognostic Nutritional Index (PNI), neutrophil to lymphocyte ratio and derived neutrophil to lymphocyte ratio, were analysed in a training cohort of 50 patients. Receiv…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyMultivariate analysisDerived neutrophil-to-lymphocyte ratio; Head and neck squamous cell carcinoma; Inflammation-based prognostic scores; Neutrophil-to-lymphocyte ratio; Overall survival; Prognostic factors; Prognostic nutritional indexoverall survivalhead and neck squamous cell carcinomaderived neutrophil-to-lymphocyte ratio03 medical and health sciences0302 clinical medicineneutrophil-to-lymphocyte ratioInternal medicinemedicine1506Stage (cooking)Neutrophil to lymphocyte ratioOriginal ResearchUnivariate analysisbusiness.industryHead and neck cancerInduction chemotherapyprognostic factorsprognostic nutritional indexmedicine.diseaseHead and neck squamous-cell carcinomaClinical trial030104 developmental biologyOncology030220 oncology & carcinogenesisinflammation-based prognostic scoresbusinessESMO open
researchProduct

Ectopic myoglobin expression is associated with a favourable outcome in head and neck squamous cell carcinoma patients

2016

BACKGROUND/AIM: Ectopic myoglobin (MB) expression, mediated by alternative and hypoxia-inducible transcription, has recently been demonstrated in several epithelial tumours. This study aimed to examine the expression of MB in hormone-independent head and neck squamous cell carcinomas (HNSCCs). PATIENTS AND METHODS: Using imunohistochemistry, ectopic MB expression was analyzed on tissue microarrays (TMAs) of 524 patients with localized and locally advanced primary and recurrent HNSCC who had undergone surgical treatment with curative intent. Associations of MB expression with survival and clinicopathological parameters were analyzed. RESULTS: MB expression was found in 45.8% of HNSCC patient…

0301 basic medicineOncologyMaleCancer ResearchPathologyCellMedizinchemistry.chemical_compound0302 clinical medicineMedicine1306 Cancer ResearchHead and neckSurgical treatmentChildTissue microarrayMyoglobinHazard ratioGeneral MedicineMiddle Aged10081 Institute of Veterinary Physiologymedicine.anatomical_structureTreatment OutcomeOncologyMyoglobinHead and Neck Neoplasms030220 oncology & carcinogenesisChild PreschoolCarcinoma Squamous CellFemale2730 OncologyAdultmedicine.medical_specialtyHPVAdolescenthead and neck squamous cell carcinoma03 medical and health sciencesYoung AdultInternal medicineHumansbusiness.industryInfant NewbornInfantmedicine.diseaseHead and neck squamous-cell carcinomaConfidence interval030104 developmental biologychemistry570 Life sciences; biologyprognosisbusiness
researchProduct

Salivary Biomarkers for Oral Squamous Cell Carcinoma Diagnosis and Follow-Up: Current Status and Perspectives.

2019

Oral cancer is the sixth most common cancer type in the world, and 90% of it is represented by oral squamous cell carcinoma (OSCC). Despite progress in preventive and therapeutic strategies, delay in OSCC diagnosis remains one of the major causes of high morbidity and mortality; indeed the majority of OSCC has been lately identified in the advanced clinical stage (i.e., III or IV). Moreover, after primary treatment, recurrences and/or metastases are found in more than half of the patients (80% of cases within the first 2 years) and the 5-year survival rate is still lower than 50%, resulting in a serious issue for public health. Currently, histological investigation represents the “gold stan…

0301 basic medicineOncologySalivamedicine.medical_specialtyPhysiologyReviewlcsh:Physiology03 medical and health sciencesliquid biopsy salivary biomarkers circulating tumor DNA extracellular vesicles microRNAs early diagnosis prognosis oral squamous cell carcinoma0302 clinical medicinesalivary biomarkersInternal medicinePhysiology (medical)microRNAMedicineLiquid biopsyStage (cooking)Survival ratecirculating tumor DNAlcsh:QP1-981liquid biopsybusiness.industryCancerGold standard (test)medicine.diseasemicroRNAsoral squamous cell carcinomastomatognathic diseases030104 developmental biology030220 oncology & carcinogenesisBiomarker (medicine)prognosisbusinessextracellular vesiclesearly diagnosisFrontiers in physiology
researchProduct

Molecular landscape of esophageal cancer: implications for early detection and personalized therapy

2018

Esophageal cancer (EC) is one of the most lethal cancers and a public health concern worldwide, owing to late diagnosis and lack of efficient treatment. Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) are main histopathological subtypes of EC that show striking differences in geographical distribution, possibly due to differences in exposure to risk factors and lifestyles. ESCC and EAC are distinct diseases in terms of cell of origin, epidemiology, and molecular architecture of tumor cells. Past efforts aimed at translating potential molecular candidates into clinical practice proved to be challenging, underscoring the need for identifying novel candidates for …

0301 basic medicineOncologymedicine.medical_specialtyEsophageal Neoplasmsmedicine.medical_treatmentEarly detectionGenomicsDiseaseAdenocarcinomaGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineHistory and Philosophy of ScienceInternal medicineEpidemiologyHumansMedicineEarly Detection of CancerEpigenomicsbusiness.industryGeneral NeuroscienceEpigenomeImmunotherapyEsophageal cancermedicine.disease030104 developmental biology030220 oncology & carcinogenesisMutationEsophageal Squamous Cell CarcinomabusinessAnnals of the New York Academy of Sciences
researchProduct

A case report of Muir-Torre syndrome in a woman with breast cancer and MSI-Low skin squamous cell carcinoma.

2017

IF 1.590; International audience; Background: The tumor spectrum in the Lynch syndrome is well defined, comprising an increased risk of developing colonic and extracolonic malignancies. Muir-Torre syndrome is a variant with a higher risk of skin disease. Patients have been described carrying mutations in the mismatch repair genes and presenting tumors with unusual histology or affected organ not part of the Lynch syndrome spectrum. Hence, the real link between Lynch syndrome, or Muir-Torre syndrome, and these tumors remains difficult to assess.Case presentation: We present the case of a 45-year-old-woman, diagnosed with breast cancer at 39 years of age and skin squamous cell carcinoma (SCC)…

0301 basic medicinePathologymedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitieslcsh:QH426-470Case Report[SDV.CAN]Life Sciences [q-bio]/CancerMLH1lcsh:RC254-282Sebaceous adenoma[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciences0302 clinical medicineSebaceous adenomaBreast cancerMuir–Torre syndromeSquamous cell carcinomaPMS2Skin Squamous Cell CarcinomaMedicineneoplasmsGenetics (clinical)MSIbusiness.industryMicrosatellite instabilitynutritional and metabolic diseasesMuir-Torre syndromeMSI-Llcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseMMRLynch syndromedigestive system diseases3. Good healthMSH2lcsh:Genetics030104 developmental biologyLynch syndromeOncologyMSH2030220 oncology & carcinogenesisCancer researchbusiness
researchProduct

The expression and prognostic relevance of programmed cell death protein 1 in tongue squamous cell carcinoma

2020

Background Programmed cell death protein 1 (PD‐1) is an immune checkpoint receptor which plays an important role in a patient´s immune responses to microbial and cancer antigens. It is expressed in tumor infiltrating lymphocytes (TILs) with many different malignancies. The aim of the study was to evaluate PD‐1 expression and its prognostic value in tongue cancer. Methods The data of tongue squamous cell carcinoma (TSCC) patients (N=81) treated in Tampere University Hospital between 1999‐2013 was used. Control data consisted of patients with non‐malignant tongue mucous membrane lesions (N=48). The formalin‐fixed paraffin‐embedded samples were stained immunohistochemically and scanned via dig…

0301 basic medicineProgrammed Cell Death 1 Receptorbiomarkkerittongue squamous cell carcinomaLYMPHOCYTES0302 clinical medicineImmunology and AllergyEPIDEMIOLOGYReceptorDISSECTIONAged 80 and over11832 Microbiology and virologyLIGAND 1 PD-L1Mucous membranemolekyylitGeneral MedicineMiddle AgedCANCER3. Good healthTongue Neoplasmsmedicine.anatomical_structure030220 oncology & carcinogenesisimmunohistochemistryCarcinoma Squamous CellSURVIVALImmunohistochemistrysyöpätauditProgrammed cell death protein 1 (PD-1)Microbiology (medical)AdultAdolescentPathology and Forensic Medicine03 medical and health sciencesYoung AdultImmune systemAntigenTonguePOOR-PROGNOSISmedicineBiomarkers TumorHumansNECKAgedmolecular markerbusiness.industryHUMAN-PAPILLOMAVIRUSCancerennusteetprogrammed cell death protein 1 (PD‐1)medicine.diseaseImmune checkpoint030104 developmental biologyCancer researchT-CELLSprognosis3111 Biomedicinebusiness
researchProduct